NEW YORK, September 23, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Alexion Pharmaceuticals, Inc. (NASDAQ:
ALXN), Arrowhead Research Corporation (NASDAQ: ARWR),
Advaxis, Inc. (NASDAQ: ADXS), Allscripts Healthcare
Solutions, Inc. (NASDAQ: MDRX), Array BioPharma Inc.
(NASDAQ: ARRY). On Tuesday, September 22,
2015, NASDAQ ended at 4,756.72, down 1.50%, DJIA declined
1.09% to finish the day at 16,330.47, and the S&P closed at
1,942.74, down 1.23%. Register for your complimentary reports at
the links given below.
--
Alexion Pharmaceuticals Inc.
--
Alexion Pharmaceuticals Inc.'s stock edged lower by 0.79% to
close Tuesday's session at USD
159.24. The company's shares oscillated between USD 156.00 and USD 159.79. The stock recorded a
trading volume of 2.25 million shares, which was above its 50-day
daily average volume of 1.68 million shares and above its 52-week
average volume of 1.56 million shares. Over the last three days
Alexion Pharmaceuticals Inc.'s shares have declined by 5.21%.
Furthermore, over the last three months the stock has lost 16.59%
and in the past six months the shares have shed 13.19%. On a
compounded total return basis, the company stock has generated
negative returns of 5.79% in the past one week and 8.38% in the
past one month. Further, the company is trading at a price to
earnings ratio of 54.53 and price to book ratio of 4.21. Sign up
and read the free notes on ALXN at:
http://www.aciassociation.com/ALXN.pdf
--
Arrowhead Research Corp
--
The stock of Arrowhead Research Corp lost 4.86% to close
Tuesday's session at USD 7.05. The
shares of the company moved in the range of USD 6.87 and USD
7.61 in trade during the day. A trading volume of 2.21
million shares was recorded, which was greater than its 150-day
daily average volume of 1.35 million shares. Over the last five
days Arrowhead Research Corp's shares have advanced 0.71% and in
the past one month the stock has gained a momentum of 27.03%.
Additionally, over the last three months the stock has declined
5.24% and in the past six months the shares have registered a loss
of 1.54%. The stock is trading at a price to book ratio of 3.19
while the historical PB ratio is close to 4.85. Register for free
on ACI Association and access the latest research on ARWR at:
http://www.aciassociation.com/ARWR.pdf
--
Advaxis Inc.
--
Advaxis Inc.'s stock increased by 0.81% to close Tuesday's
session at USD 16.12. The company's
shares fluctuated in the range of USD
15.68 and USD 17.04. A total
of 1.99 million shares exchanged hands, which surpassed its 50-day
daily average volume of 1.19 million shares and was above its
52-week average volume of 1.22 million shares. Over the last three
days Advaxis Inc.'s shares have declined by 18.21% and in the past
one week the stock has moved down 17.12%. The company stock has
shown a negative return of 22.76% in the past three months and a
positive return of 28.55% in the last half year, on a compounded
total return basis. The complete research on ADXS is available for
free at: http://www.aciassociation.com/ADXS.pdf
--
Allscripts Healthcare Solutions Inc.
--
Allscripts Healthcare Solutions Inc.'s stock slipped by 2.03% to
close Tuesday's session at USD 13.55.
The company's shares oscillated between USD
13.45 and USD 13.73 in trade during the day. The stock
recorded a trading volume of 1.93 million shares, which was below
its 50-day daily average volume of 3.18 million shares and below
its 52-week average volume of 2.99 million shares. Over the last
five days Allscripts Healthcare Solutions Inc.'s shares have
declined by 0.70% and in the past one month the stock has lost
1.63%. In addition, over the last three months the stock has lost
6.07% and year to date the shares have picked up 6.07%. The stock
is trading at a price to book ratio of 1.85 and price to sales
ratio of 1.86. Free in-depth research on MDRX is available at:
http://www.aciassociation.com/MDRX.pdf
--
Array Biopharma Inc.
--
Array Biopharma Inc.'s stock declined 3.36% to close Tuesday's
session at USD 5.18. The share price
vacillated between USD 5.10 and USD
5.33. The stock recorded a trading volume of 1.87 million
shares, which was above its 50-day daily average volume of 1.70
million shares and below its 52-week average volume of 2.17 million
shares. Over the last three days Array Biopharma Inc.'s shares have
declined by 12.35% and in the past one week the stock has moved
down 12.20%. Moreover, in the last six months the stock has lost
34.01% and year to date the shares have picked up 9.51%. Further,
the company is trading at a price to earnings ratio of 518.00 and
price to book ratio of 17.26. Additionally, the stock is trading at
a price to sales ratio of 14.20. The complimentary notes on ARRY
can be downloaded in PDF format at:
http://www.aciassociation.com/ARRY.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com